Skip to main content
Clinical Trials/NCT01772602
NCT01772602
Recruiting
Not Applicable

The National Amyotrophic Lateral Sclerosis Registry

Centers for Disease Control and Prevention2 sites in 1 country30,000 target enrollmentOctober 1, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Amyotrophic Lateral Sclerosis
Sponsor
Centers for Disease Control and Prevention
Enrollment
30000
Locations
2
Primary Endpoint
The National Amyotrophic Lateral Sclerosis (ALS) Registry
Status
Recruiting
Last Updated
3 days ago

Overview

Brief Summary

The purpose of this registry is to (A) better describe the incidence and prevalence of Amyotrophic Lateral Sclerosis (ALS) in the United States;(B) examine appropriate factors, such as environmental and occupational, that may be associated with the disease; (C) better outline key demographic factors (such as age, race or ethnicity, gender, and family history of individuals who are diagnosed with the disease) associated with the disease; and (D) better examine the connection between ALS and other motor neuron disorders that can be confused with ALS, misdiagnosed as ALS, and in some cases progress to ALS.

Detailed Description

The National ALS Registry's Research Notification System allows person with ALS to participate in clinical trials.

Registry
clinicaltrials.gov
Start Date
October 1, 2010
End Date
December 1, 2040
Last Updated
3 days ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • \- U.S. citizens 18 years of age or older

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

The National Amyotrophic Lateral Sclerosis (ALS) Registry

Time Frame: 1 year

To determine the incidence and prevalence of Amyotrophic Lateral Sclerosis in the US.

Secondary Outcomes

  • Risk factors of ALS(1 year)

Study Sites (2)

Loading locations...

Similar Trials